SAE1抗体

+ +

•  

   

     Gel: 15%SDS-PAGE, Lysate: 40 μg, Lane 1-2: 293T cells, A431 cells, Primary antibody: P07919(SAE1 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07919(SAE1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07919(SAE1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of SAE1 Antibody**

SAE1 (SUMO-activating enzyme subunit 1) is a critical component of the SUMOylation pathway, a post-translational modification system that regulates protein localization, stability, and interactions. SAE1 forms a heterodimer with SAE2 to constitute the E1 activating enzyme, which initiates SUMO (Small Ubiquitin-like Modifier) conjugation by ATP-dependent activation of SUMO proteins. This process is essential for diverse cellular functions, including transcriptional regulation, DNA repair, and stress responses.

SAE1 antibodies are valuable tools for studying SUMOylation dynamics. They enable the detection of SAE1 expression levels, localization, and interaction partners in various experimental setups, such as Western blotting, immunofluorescence, and immunoprecipitation. Dysregulation of SAE1 has been implicated in diseases, particularly cancer. Overexpression of SAE1 is observed in malignancies like melanoma and neuroblastoma, correlating with tumor progression and poor prognosis. Conversely, SAE1 inhibition disrupts SUMOylation, leading to impaired oncogenic signaling and apoptosis in cancer cells, highlighting its therapeutic potential.

Research using SAE1 antibodies also explores its role in neurodegenerative disorders and viral infections, where SUMOylation modulates host-pathogen interactions. These antibodies aid in validating SAE1 as a biomarker or drug target in preclinical models. Overall, SAE1 antibodies are pivotal in dissecting the molecular mechanisms of SUMOylation and advancing therapeutic strategies targeting this pathway.